Studies immune signals in blood and marrow of people with acute myeloid leukemia
Collects blood and marrow samples from newly diagnosed adults with leukemia before and after treatment.
Plain-language title generated from the registry record
Registry title: Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
Key facts
- Where
- Milan and Reggio Calabria, ItalySee the 2 sites
Where in Italy
- IRCCS Ospedale San RaffaeleMilan, ItalyTaking people
- GOM Bianchi Melacrino MorelliReggio Calabria, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ciceri Fabio
- Trial code
- NCT06535113
- Record updated
- 8 June 2026
- Original description
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.Read full original descriptionShow less
Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
Inclusion: Any gender,; Adults (>18 years old),; New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria); Capable of comprehend the study and the consent form,; Willing to sign the informed consent for the study; For the retrospective population we will select:; biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.
Exclusion: Pediatric patients (<18 years old),; Patients unable or unwilling to sign the informed consent.